173 related articles for article (PubMed ID: 10809954)
21. The functional role of class II-associated invariant chain peptide (CLIP) in its ability to variably modulate immune responses.
Chaturvedi P; Hengeveld R; Zechel MA; Lee-Chan E; Singh B
Int Immunol; 2000 Jun; 12(6):757-65. PubMed ID: 10837403
[TBL] [Abstract][Full Text] [Related]
22. Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells.
Costantino CM; Ploegh HL; Hafler DA
J Immunol; 2009 Jul; 183(2):945-52. PubMed ID: 19553543
[TBL] [Abstract][Full Text] [Related]
23. Mechanism and regulation of antigen processing by cathepsin B.
Katunuma N; Matsunaga Y; Saibara T
Adv Enzyme Regul; 1994; 34():145-58. PubMed ID: 7942272
[TBL] [Abstract][Full Text] [Related]
24. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus.
Nakagawa T; Roth W; Wong P; Nelson A; Farr A; Deussing J; Villadangos JA; Ploegh H; Peters C; Rudensky AY
Science; 1998 Apr; 280(5362):450-3. PubMed ID: 9545226
[TBL] [Abstract][Full Text] [Related]
25. Peptide analogs with different affinites for MHC alter the cytokine profile of T helper cells.
Chaturvedi P; Yu Q; Southwood S; Sette A; Singh B
Int Immunol; 1996 May; 8(5):745-55. PubMed ID: 8671663
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells.
Robson NC; Donachie AM; Mowat AM
Eur J Immunol; 2008 May; 38(5):1238-46. PubMed ID: 18398931
[TBL] [Abstract][Full Text] [Related]
27. TLR2- and 4-independent immunomodulatory effect of high molecular weight components from Ascaris suum.
Favoretto BC; Silva SR; Jacysyn JF; Câmara NO; Faquim-Mauro EL
Mol Immunol; 2014 Mar; 58(1):17-26. PubMed ID: 24263181
[TBL] [Abstract][Full Text] [Related]
28. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
29. Proteases involved in MHC class II antigen presentation.
Villadangos JA; Bryant RA; Deussing J; Driessen C; Lennon-Duménil AM; Riese RJ; Roth W; Saftig P; Shi GP; Chapman HA; Peters C; Ploegh HL
Immunol Rev; 1999 Dec; 172():109-20. PubMed ID: 10631941
[TBL] [Abstract][Full Text] [Related]
30. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation.
Maurer D; Fiebiger E; Reininger B; Ebner C; Petzelbauer P; Shi GP; Chapman HA; Stingl G
J Immunol; 1998 Sep; 161(6):2731-9. PubMed ID: 9743330
[TBL] [Abstract][Full Text] [Related]
31. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
[TBL] [Abstract][Full Text] [Related]
32. Soluble protein but not peptide administration diverts the immune response of a clonal CD4+ T cell population to the T helper 2 cell pathway.
Degermann S; Pria E; Adorini L
J Immunol; 1996 Oct; 157(8):3260-9. PubMed ID: 8871620
[TBL] [Abstract][Full Text] [Related]
33. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.
Saegusa K; Ishimaru N; Yanagi K; Arakaki R; Ogawa K; Saito I; Katunuma N; Hayashi Y
J Clin Invest; 2002 Aug; 110(3):361-9. PubMed ID: 12163455
[TBL] [Abstract][Full Text] [Related]
34. Human invariant chain isoform p35 restores thymic selection and antigen presentation in CD74-deficient mice.
Genève L; Chemali M; Desjardins M; Labrecque N; Thibodeau J
Immunol Cell Biol; 2012 Oct; 90(9):896-902. PubMed ID: 22689013
[TBL] [Abstract][Full Text] [Related]
35. Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E.
Bennett K; Levine T; Ellis JS; Peanasky RJ; Samloff IM; Kay J; Chain BM
Eur J Immunol; 1992 Jun; 22(6):1519-24. PubMed ID: 1601038
[TBL] [Abstract][Full Text] [Related]
36. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
[TBL] [Abstract][Full Text] [Related]
37. Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation.
Ohmura M; Yamamoto M; Tomiyama-Miyaji C; Yuki Y; Takeda Y; Kiyono H
Infect Immun; 2005 Jul; 73(7):4088-97. PubMed ID: 15972497
[TBL] [Abstract][Full Text] [Related]
38. Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages.
Beers C; Honey K; Fink S; Forbush K; Rudensky A
J Exp Med; 2003 Jan; 197(2):169-79. PubMed ID: 12538657
[TBL] [Abstract][Full Text] [Related]
39. Lack of Th1 or Th2 polarization of CD4+ T cell response induced by particulate antigen targeted to phagocytic cells.
Sedlik C; Dériaud E; Leclerc C
Int Immunol; 1997 Jan; 9(1):91-103. PubMed ID: 9043951
[TBL] [Abstract][Full Text] [Related]
40. Anti-T-cell humoral and cellular responses in healthy BALB/c mice following immunization with ovalbumin or ovalbumin-specific T cells.
Zhang XY; Liu XG; Wang W; Wang WC; Gao XM
Immunology; 2003 Apr; 108(4):465-73. PubMed ID: 12667208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
